Details for Patent: 9,872,854
✉ Email this page to a colleague
Which drugs does patent 9,872,854 protect, and when does it expire?
Patent 9,872,854 protects OTEZLA and is included in one NDA.
This patent has eight patent family members in eight countries.
Summary for Patent: 9,872,854
Title: | Methods for the treatment of psoriatic arthritis using apremilast |
Abstract: | Methods of treating, managing or preventing psoriatic arthritis are disclosed. Specific methods encompass the administration of apremilast, alone or in combination with a second active agent. |
Inventor(s): | Day; Robert (Newtown, PA) |
Assignee: | Celgene Corporation (Summit, NJ) |
Application Number: | 14/209,874 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,872,854 |
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Recent additions to Drugs Protected by US Patent 9,872,854
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amgen Inc | OTEZLA | apremilast | TABLET | 205437 | Mar 21, 2014 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | U-2232 | TREATMENT OF PSORIATIC ARTHRITIS USING A DOSAGE TITRATION SCHEDULE | |||
Amgen Inc | OTEZLA | apremilast | TABLET | 205437 | Mar 21, 2014 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | U-2233 | TREATMENT OF PSORIATIC ARTHRITIS WITH APREMILAST USING A DOSAGE TITRATION SCHEDULE AND A SECOND ACTIVE AGENT | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 9,872,854
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amgen Inc | OTEZLA | apremilast | TABLET;ORAL | 205437-001 | Mar 21, 2014 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF PSORIATIC ARTHRITIS USING A DOSAGE TITRATION SCHEDULE | ⤷ Try a Trial | |||
Amgen Inc | OTEZLA | apremilast | TABLET;ORAL | 205437-001 | Mar 21, 2014 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF PSORIATIC ARTHRITIS WITH APREMILAST USING A DOSAGE TITRATION SCHEDULE AND A SECOND ACTIVE AGENT | ⤷ Try a Trial | |||
Amgen Inc | OTEZLA | apremilast | TABLET;ORAL | 205437-002 | Mar 21, 2014 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF PSORIATIC ARTHRITIS USING A DOSAGE TITRATION SCHEDULE | ⤷ Try a Trial | |||
Amgen Inc | OTEZLA | apremilast | TABLET;ORAL | 205437-002 | Mar 21, 2014 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF PSORIATIC ARTHRITIS WITH APREMILAST USING A DOSAGE TITRATION SCHEDULE AND A SECOND ACTIVE AGENT | ⤷ Try a Trial | |||
Amgen Inc | OTEZLA | apremilast | TABLET;ORAL | 205437-003 | Mar 21, 2014 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF PSORIATIC ARTHRITIS USING A DOSAGE TITRATION SCHEDULE | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,872,854
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2014235273 | ⤷ Try a Trial | |||
Brazil | 112015020584 | ⤷ Try a Trial | |||
China | 105050624 | ⤷ Try a Trial | |||
Hong Kong | 1215671 | ⤷ Try a Trial | |||
South Korea | 20150126618 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |